# Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria

> **NCT00519467** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 120 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Chlorproguanil-dapsone-artesunate (CDA)

## Key facts

- **NCT ID:** NCT00519467
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519467, "Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00519467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*